Oncology: Clinical Therapy and Diagnosis -> Clinical Diagnosis -> GU 1573

1573 - Prospective evaluation of18F- DCFPyL in Patients with Biochemically Recurrent Prostate Cancer: Positivity Rate and Correlation with PSA levels (ID 1314)

Session Name
Prostate/GU Imaging Posters
Speakers
Authors
Presentation Topic
Oncology: Clinical Therapy and Diagnosis -> Clinical Diagnosis -> GU
Presentation Number
1573

Previous Eposter
1571 - COMPARISON OF 68Ga-PSMA PET-CT WITH CONVENTIONAL IMAGING IN LOCALIZATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER (ID 1312)

Next Eposters
1576 - [18F]-fluciclovine positivity rate is not affected by androgen deprivation therapy (ADT) in recurrent prostate cancer post-prostatectomy. (ID 1317)
1579 - The role of 68Ga-PSMA-PET/CT after a negative 18F-Choline PET/CT in biochemical relapse of prostate cancer: Initial experience (ID 1320)
1580 - [18F] fluciclovine PET/CT is superior to conventional imaging in preoperative nodal staging in patients with high-risk prostate cancer
(ID 1321)
1581 - Will next-generation PET lead to revised criteria for castration resistant prostate cancer? (ID 1322)
1584 - Prospective Comparison of 18F-DCFPyL PET/CT with 18F-NaF PET/CT for Detection of Skeletal Metastases in Biochemically Recurrent Prostate Cancer (ID 1325)
1585 - Celiac Ganglia in 18F-Fluciclovine PET/CT Scan: Is It a Potential Pitfall for False Positive Reading? (ID 1326)
1592 - Prognostic value of automatically acquired biomarkers using artificial intelligence in 18F-Choline PET/CT in high-risk prostate cancer. (ID 1340)
1595 - Optimized beta-value of block sequential regularized expectation maximization (BSREM) reconstruction for rapid whole-body scan on FDG PET/MRI (ID 1343)
1596 - Transitioning New Technology into the Reading Room: A Reconstruction Approach for New Digital PET Users (ID 1344)
1601 - Effect of Bayesian penalized-likelihood PET reconstruction condition on quantitation. (ID 1349)